Abstract
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder affecting millions of people worldwide. The etiology of AD is not known, and intense research involving multimodal neuroimaging data (e.g., MRI, functional MRI, PET etc.) is extensively used to identify the causal molecular process for AD. In this context, various imaging-based databases accessible to researchers globally, are useful for an independent analysis. Apart from MRI-based brain imaging data, the neurochemical data using magnetic resonance spectroscopy (MRS) provide early molecular processes before the structural or functional changes are manifested. The existing imaging-based databases in AD lack the integration of MRS modality and, thus, limits the availability of neurochemical information to the AD research community. This perspective is an initiative to bring attention to the development of the neuroimaging database, “ANSH,” that includes brain glutathione (GSH), gamma aminobutyric acid (GABA) levels, and other neurochemicals along with MRI-based information for AD, mild cognitive impairment (MCI), and healthy subjects. ANSH is supported by a JAVA-based workflow environment and python providing a simple, dynamic, and distributed platform with data security. The platform consists of two-tiered architecture for data collection and management further supporting quality control, report generation for analyzed data, and data backup with a dedicated storage system. The ANSH database aims to present a single neuroimaging data platform incorporating diverse data types from healthy control and patient groups to provide better insights pertaining to disease progression. This data management platform provides flexible data sharing across users with continuous project monitoring. The development of ANSH platform will facilitate collaborative research and multi-site data sharing across the globe.
Highlights
Alzheimer’s disease (AD) is a major neurodegenerative disorder, and the number of AD patients is increasing globally with each passing year, and disease-modifying treatment is not available
Neurochemical data is added in the present dataset ‘‘ANSH’’ to bridge the gap (Figure 1)
MR spectroscopy (MRS) is a potent non-invasive modality to identify the various neurochemicals involved in the early disease process
Summary
Alzheimer’s disease (AD) is a major neurodegenerative disorder, and the number of AD patients is increasing globally with each passing year, and disease-modifying treatment is not available. Neuroimaging modalities involving MRI, fMRI, PET, and behavioral studies have provided the associated structural and behavioral changes in the disease process (Gorgolewski et al, 2016) The first such database was reported by the National Alzheimer’s Coordinating Center (NACC), which mainly involved MRI, and the genetic and behavioral dataset of healthy old (HO), and AD patients (CroninStubbs et al, 2000; Beekly et al, 2004). These databases created an opportune situation for the sharing of imagingbased data with researchers. ANSH is the first platform where antioxidant, neurotransmitter, and energy metabolites are discussed and will be available to the research community
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
